Maxim Group set a $6.00 price objective on Vistagen Therapeutics (NASDAQ:VTGN) in a research note published on Thursday morning, TipRanks reports. The firm currently has a buy rating on the stock.
Separately, ValuEngine downgraded Vistagen Therapeutics from a buy rating to a hold rating in a research note on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $8.30.
NASDAQ:VTGN traded up $0.01 during midday trading on Thursday, reaching $0.56. 1,377,889 shares of the company traded hands, compared to its average volume of 325,822. Vistagen Therapeutics has a twelve month low of $0.54 and a twelve month high of $2.44. The firm has a market capitalization of $23.87 million, a P/E ratio of -0.51 and a beta of -0.42.
Institutional investors have recently made changes to their positions in the business. Millennium Management LLC bought a new stake in Vistagen Therapeutics during the 4th quarter valued at $28,000. Northern Trust Corp raised its stake in Vistagen Therapeutics by 168.6% during the 4th quarter. Northern Trust Corp now owns 69,642 shares of the company’s stock valued at $104,000 after acquiring an additional 43,714 shares in the last quarter. D.A. Davidson & CO. raised its stake in Vistagen Therapeutics by 22.9% during the 4th quarter. D.A. Davidson & CO. now owns 94,000 shares of the company’s stock valued at $141,000 after acquiring an additional 17,500 shares in the last quarter. Geode Capital Management LLC raised its stake in Vistagen Therapeutics by 13.0% during the 4th quarter. Geode Capital Management LLC now owns 154,457 shares of the company’s stock valued at $231,000 after acquiring an additional 17,721 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Vistagen Therapeutics by 42.7% during the 3rd quarter. Vanguard Group Inc. now owns 257,465 shares of the company’s stock valued at $373,000 after acquiring an additional 77,090 shares in the last quarter. 7.28% of the stock is currently owned by hedge funds and other institutional investors.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Recommended Story: Options Trading – Understanding Strike Price
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.